During the corresponding time, Elite Pharmaceuticals Inc saw a revenue deteriorated by -17.52 % year on year, sequentially revenue fell by -20.6 %. While revenue at the Elite Pharmaceuticals Inc 's corporate clients
Elite Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company markets and distributes pharmaceutical products, including Phentermine (37.5mg, 15mg, 30mg), Hydromorphone 8mg, and Naltrexone 50mg, through its subsidiary TAGI in the United States, Puerto Rico, and Canada. It held exclusive marketing rights in the United States and Puerto Rico and non-exclusive rights in Canada under the Precision Dose License Agreement, which expired on September 10, 2025, receiving license fees and milestone payments during the term. The company entered a non-exclusive license agreement with Prasco, LLC and its affiliate Burel to manufacture, supply, and distribute generic mixed amphetamine extended-release capsules in the United States from January 1, 2024, until March 31, 2025. Under the Pyros Manufacturing and Supply Agreement, the company manufactured and packaged Sabril for Pyros until the agreement was mutually terminated on January 10, 2025. The Dexcel Agreement for Israel involves manufacturing and packaging Amphetamine IR products under Dexcel's label, with Dexcel responsible for sales, marketing, and distribution; the first shipment occurred in July 2025. Additionally, the company is developing proprietary abuse-deterrent opioid products utilizing its pharmacological abuse-deterrent technology.
Elite Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company markets and distributes pharmaceutical products, including Phentermine (37.5mg, 15mg, 30mg), Hydromorphone 8mg, and Naltrexone 50mg, through its subsidiary TAGI in the United States, Puerto Rico, and Canada. It held exclusive marketing rights in the United States and Puerto Rico and non-exclusive rights in Canada under the Precision Dose License Agreement, which expired on September 10, 2025, receiving license fees and milestone payments during the term. The company entered a non-exclusive license agreement with Prasco, LLC and its affiliate Burel to manufacture, supply, and distribute generic mixed amphetamine extended-release capsules in the United States from January 1, 2024, until March 31, 2025. Under the Pyros Manufacturing and Supply Agreement, the company manufactured and packaged Sabril for Pyros until the agreement was mutually terminated on January 10, 2025. The Dexcel Agreement for Israel involves manufacturing and packaging Amphetamine IR products under Dexcel's label, with Dexcel responsible for sales, marketing, and distribution; the first shipment occurred in July 2025. Additionally, the company is developing proprietary abuse-deterrent opioid products utilizing its pharmacological abuse-deterrent technology.
Sources:
Elite Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Elite Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Elite Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.68 %